Nuvalent
Nuvalent is creating precisely targeted therapies for patients with cancer.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Nuvalent is a company in Cambridge, United States, that is creating precisely targeted therapies for patients with cancer, with deep expertise in chemistry and structure-based drug discovery.
History
Nuvalent is a company in Cambridge, United States. According to its official website, Nuvalent is creating precisely targeted therapies for patients with cancer, with deep expertise in chemistry and structure-based drug discovery.
Recent events
Reported
Nuvalent appoints Emily Drabant Conley to its board[3]
Nuvalent announced the appointment of Emily Drabant Conley, CEO of Federation Bio, to its Board of Directors.
Reported
Nuvalent reports third-quarter 2021 financial results[4]
Nuvalent reported its third-quarter 2021 financial results and pipeline progress.
Reported
FDA clears Nuvalent’s NVL-520 IND application[5]
The U.S. FDA cleared Nuvalent’s Investigational New Drug application for NVL-520, enabling the company to proceed toward clinical testing. Nuvalent said it was preparing to initiate the Phase 1 portion of a global Phase 1/2 trial in the second half of 2021.
Reported
Nuvalent appoints chief legal officer and board director[5]
Nuvalent reported appointing Deborah Miller as chief legal officer and Sapna Srivastava to its board of directors.
Reported
Nuvalent completes $190.6 million IPO[5]
Nuvalent completed its upsized initial public offering, selling 11,212,500 shares at $17.00 per share and raising approximately $190.6 million in gross proceeds before expenses.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/nuvalent · Editorial policy · How profiles are compiled